All In Biotech

Drug Trial Radar · NCT03552276

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

281

Actual

Start

Jul 11, 2018

Primary completion

Sep 18, 2023

Study completion Sep 18, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab

Conditions

  • Psoriatic Arthritis

Interventions

  • SUNPG18_07 I (Tildrakizumab 200 mg)Drug

    injection

  • SUNPG18_07 II (Tildrakizumab 100 mg)Drug

    injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: upto week 208

Locations

66 sites in 8 countries. Site status is shown where the registry gives one.

  • Site 25

    Glendale, Arizona

  • Site 16

    Phoenix, Arizona

  • Site 14

    Denver, Colorado

  • Site 27

    Wichita, Kansas

  • Site 23

    Lexington, Kentucky

  • Site 20

    Monroe, Louisiana

  • Site 26

    Lebanon, New Hampshire

  • Site 24

    Salisbury, North Carolina

  • Site 19

    Cincinnati, Ohio

  • Site 17

    Middleburg Heights, Ohio

  • Site 18

    Memphis, Tennessee

  • Site 21

    Seattle, Washington

  • Site 22

    Spokane, Washington

  • Site 02

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Site 01

    Mar del Plata, Buenos Aires, Argentina

  • Site 03

    San Fernando, Buenos Aires, Argentina

  • Site 32

    Budapest, Hungary

  • Site 34

    Budapest, Hungary

  • Site 33

    Kistarcsa, Hungary

  • Site 11

    Chihuahua City, Mexico

  • Site 08

    Cuautitlán Izcalli, Mexico

  • Site 10

    Durango, Mexico

  • Site 09

    Mexico City, Mexico City, Mexico

  • Site 05

    Mexico City, Mexico City, Mexico

  • Site 06

    Monterrey, Nuevo León, Mexico

  • Site 13

    San Luis Potosí City, San Luis Potosí, Mexico

  • Site 04

    San Luis Potosí City, San Luis Potosí, Mexico

  • Site 07

    Culiacán, Sinaloa, Mexico

  • Site 12

    Mérida, Yucatán, Mexico

  • Site 38

    Bialystok, Poland

  • Site 47

    Bytom, Poland

  • Site 36

    Elblag, Poland

  • Site 39

    Katowice, Poland

  • Site 40

    Katowice, Poland

  • Site 46

    Krakow, Poland

  • Site 43

    Lodz, Poland

  • Site 48

    Nowa Sól, Poland

  • Site 42

    Poznan, Poland

  • Site 53

    Sochaczew, Poland

  • Site 50

    Warsaw, Poland

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.